I
nterleukin-17 (IL-17A) is the best characterized member of a newly described cytokine family (1) . Consisting of six ligands and five receptors, the IL-17 family shares minimal homology with other cytokines, and little is known about its mechanisms of signaling. IL-17 is produced primarily by T cells, particularly CD4 ϩ but also CD8ϩ and ␥␦ populations (2) (3) (4) . In the classic view of T cell differentiation, T helper cells are divided into Th1 and Th2 subsets based on cytokine profiles. A major insight into IL-17's place in the immune network was made with the discovery that IL-23 promotes IL-17 expression in a unique CD4 ϩ T cell population (5, 6) , now termed ''Th17'' (7) . Development of Th17 cells in mice is driven by TGF␤ and IL-6 (8-10) via the ROR␥t transcription factor (11) . Th17 cells produce IL-17 as well as IL-17F, TNF␣, IL-6, and IL-22 (12, 13) and regulate various aspects of inflammation and autoimmunity.
The discovery of the Th17 subset resolved important ambiguities that were not adequately explained by the Th1/Th2 paradigm. For example, several diseases considered to be Th1-dominated nonetheless can develop in mice deficient in Th1 cytokines such as IL-12 or IFN␥ (14, 15) . Moreover, Th17 cells, IL-17, and/or IL-23 are sufficient to drive pathology in various autoimmune models, particularly rheumatoid arthritis (RA) and EAE (14, (16) (17) (18) (19) . Indeed, IL-17 is elevated in human RA (20) , blocking IL-17 in collageninduced arthritis (CIA) reduces disease (21) , overexpression of IL-17 causes arthritis in rodents (22) , and IL-17 KO (23) or ICOS KO mice (which cannot make IL-17) are also resistant to CIA (24) . In addition, IL-17 negatively impacts certain infectious conditions, such as Shistosomiasis and Helicobacter pylori infections (25) (26) (27) (28) . Accordingly, IL-17 is considered an appealing target for new anticytokine therapies (29) . In contrast to its pathological properties, IL-17 is essential for mounting effective responses to many extracellular microbes, largely through regulation of neutrophil migration and granulopoiesis (30) (31) (32) (33) .
Surprisingly little is known about the nature of the IL-17R complex or its mechanisms of signaling. The first IL-17 binding protein to be identified was IL-17RA, a single transmembrane receptor with an unusually long cytoplasmic tail and almost no homology to known receptors (34) . IL-17RA is ubiquitously expressed at the mRNA level, although surface expression varies widely (34, 35) . Recent studies showed that IL-17RA is part of a preassembled complex that undergoes major conformational alterations after ligand binding (36) . Moreover, another IL-17R superfamily member, IL-17RC, has been implicated in IL-17-mediated signal transduction (37) . Thus, the IL-17R is a multimeric complex with dynamic subunit interactions.
The signaling pathways induced by IL-17 are just beginning to be elucidated. IL-17 induces most of the same genes as IL-1␤ and TLR ligands (38) , and a complex bioinformatics analysis predicted a potential Toll-IL-1 Receptor (TIR)-like signaling domain in IL-17R family members, termed ''SEFIR'' (39) . TRAF6 is necessary for IL-17 target gene expression (40) , and two new reports show that the Act1 adaptor is downstream of IL-17 (41, 42) . Both TRAF6 and Act1 are needed to activate NF-B, and the majority of IL-17 target genes are NF-B-dependent (35) . In addition, IL-17 activates CCAAT/Enhancer binding proteins (C/EBP), particularly C/EBP␤ and C/EBP␦, which are also vital for target gene expression (35, 43) . Currently, very little is known about how IL-17 connects to C/EBP proteins or whether C/EBP␤ and C/EBP␦ are functionally redundant.
The goal of this study was to define motifs within IL-17RA that mediate signaling. Using bioinformatics and genetic approaches, we found that a membrane-proximal region encompassing the SEFIR domain is necessary for activation of NF-B, ERK, and C/EBP and subsequent gene expression. We also identified a critical extension of this region with homology to a TIR BB-loop that is absolutely required for IL-17 function. In addition, a separable signaling motif was located in the C-terminal region of the IL-17RA cytoplasmic tail that contributes to activation of C/EBP␤ but not C/EBP␦, as well as a subset of IL-17 target genes. This identifies functional subdomains in any IL-17R family member and establishes a basis to analyze this unique receptor family.
Results
System for Evaluating Functional Domains of IL-17RA. IL-17 receptors are notably distinct from other cytokine receptors in amino acid sequence (1) . However, a domain with similarity to the well studied TIR domain was predicted based on sophisticated biostatistical methods, termed a ''SEFIR'' domain, for SEF (''similar expression to FGF receptor'') and IL-17R (39) (Fig. 1A) . However, the SEFIR domain lacks important structural elements found in bona fide TIR domains, such as the ''BB loop'' known to be crucial for interactions between TIR-containing molecules (44) . To gain insight into structure-function relationships within IL-17RA, we performed scanning and alignment of the IL-17RA cytoplasmic tail with IL-1 and TLR family members. We identified a short region downstream and slightly overlapping the SEFIR motif with homology to a BB-loop (Fig. 1B) . This domain contains the glutamic acid and arginine residues that are conserved in all IL-1 and TLR BB domains (blue) (45) as well as a number of additional residues shared with IL-1R but not TLR family receptors (green). Finally, there is a valine at position 553 whose location is homologous to a valine in Drosophila Toll, where mutation destroys function (44) . This site also aligns with proline-712 in murine TLR4, where a naturally occurring mutation to histidine blocks TLR4 function in LPS-resistant strains of mice (44, 46) . We term this motif the ''TIR-like loop'' (TILL), which we hypothesized may be important for mediating IL-17RA-dependent signaling.
To date, structure-function studies of IL-17RA have been technically challenging because of its ubiquitous expression (34) . Therefore, we immortalized tail tip fibroblasts (MFs) from IL-17RA KO mice. This system is relevant for evaluating IL-17RA function, because cells of mesenchymal origin such as fibroblasts, osteoblasts, and stromal cells are highly responsive to IL-17 (38, 47) . To define regions of IL-17RA important for signaling, we created HA-tagged internal deletions and point mutations of the SEFIR and TILL domains [ Fig. 1 and supporting information (SI) Fig. 6 ]. Constructs were transfected into IL-17RA KO MF cells, and lines that expressed high, comparable levels of receptor were chosen for analysis (SI Fig.  6A ). The ability of each mutant to bind IL-17 also was verified (SI Fig. 7 ). In some clones, IL-17RA expression diminished over time, so expression of IL-17RA was monitored for each clone within 2 days of all experiments (data not shown).
The SEFIR and TILL Domains Are Necessary for IL-17-Dependent
Signaling. We and others have identified panels of IL-17 target genes in mesenchymal cell types (38, 47) . We used representative genes to monitor signaling by the IL-17RA mutants described above, including IL-6, 24p3, and CXCL5 (LIX) and C/EBP␦. The full length (FL) IL-17RA and the IL-17RA⌬665 deletion both induced strong secretion of IL-6 after IL-17 treatment. Similar results were seen with IL-17 in combination with suboptimal doses of TNF␣ ( Fig. 2A ). As shown, the dose of TNF␣ used in these experiments did not trigger appreciable IL-6 expression. Cells expressing the IL-17RA⌬527 mutant, which deletes the TILL and part of the SEFIR, did not produce IL-6 after IL-17 and/or TNF␣ treatment. Consistently, the IL-17RA⌬426 mutant was completely defective in IL-17 signaling to IL-6. Finally, deletion of either the SEFIR or TILL domains individually resulted in a failure to respond to IL-17 ( Fig. 2 A) . A similar pattern was seen for IL-17 induction of 24p3, CXCL5, and CXCL1; that is, IL-17RA.FL and IL-17RA⌬665 induced IL-17-dependent expression, whereas receptors lacking the SEFIR or TILL domains failed to respond to IL-17 ( Fig. 2 B and C and data not shown). Also consistent with this, activation of the 24p3 promoter was induced by IL-17RA.FL and IL-17RA⌬665 but not by deletions lacking SEFIR and/or TILL (data not shown). Because IL-6, 24p3, CXCL5, and CXCL1 are regulated by NF-B, we examined the ability of IL-17RA mutants to activate NF-B by EMSA. As expected, IL-17RA.FL triggered a strong DNA binding activity (Fig. 2D) , which was confirmed to be NF-B by competition and supershifting (data not shown). The IL-17RA⌬665 mutant induced NF-B to a similar magnitude, but the IL-17RA⌬SEFIR and IL-17RA⌬TILL mutants failed to induce NF-B. Thus, the SEFIR and TILL domains mediate NF-B activation and expression of NF-B-dependent genes.
IL-17 has been reported to activate various MAPK pathways, and AP1 sites are statistically overrepresented in IL-17 target promoters (35, 40, (48) (49) (50) . Neither p38 nor JNK were activated by IL-17 in this cell background (data not shown). However, activation of ERK1/2 was preserved in the FL and IL-17RA⌬665 mutant, but not in receptors with mutations in SEFIR or TILL (Fig. 2E) . Therefore, the SEFIR/TILL motif is also upstream of ERK.
C/EBP␤ Is Activated by Two Distinct Domains Within IL-17RA. C/EBP␤ and C/EBP␦ are key transcription factors activated by IL-17, and both IL-6 and 24p3 contain essential C/EBP sites in their proximal promoters (35, 43) . The mechanism by which IL-17 activates C/EBP is unclear, but expression of C/EBP␤ and C/EBP␦ mRNA and protein are enhanced in response to IL-17 and/or TNF␣. Moreover, overexpression of C/EBP␤ or C/EBP␦ can partially substitute for IL-17 signaling (38, 43) . Here, we show that the TILL and SEFIR domains are required for up-regulation of C/EBP␦ (Fig. 3 A and B) . C/EBP␤ mRNA was not substantially enhanced by IL-17 and/or TNF␣ in IL-17RA.FL cells (data not shown). However, the LAP* isoform of C/EBP␤ was strongly induced in IL-17RA.FL but not IL-17RA KO , IL-17RA⌬SEFIR, or IL-17RA⌬TILL cells. Unex- pectedly, IL-17-mediated induction of C/EBP␤ was impaired in IL-17RA⌬665 cells (Fig. 3B) , indicating that C/EBP␤ expression also is regulated by a region downstream of residue 665. Consistent with this observation, IL-17-mediated induction of C/EBP DNA binding was reduced in cells expressing IL-17RA⌬665 compared with IL-17RA.FL (Fig. 3C) . In light of this finding, it was surprising that IL-17 induction of 24p3, IL-6, and CXCL5 were not compromised in IL-17RA⌬665-expressing cells (Fig. 2) . However, expression of CCL2 and CCL7 were reduced in IL-17RA⌬665 cells (Fig.  3D) , suggesting that certain genes may have a stronger dependence on C/EBP␤ than others. Collectively, these data indicate that (i) expression of both C/EBP␦ and C/EBP␤ is regulated through the SEFIR/TILL domain, (ii) regulation of C/EBP␤ also involves signals from a distal region in the IL-17RA tail, and (iii) signals through this distal domain activate some but not all IL-17 target genes (SI Fig. 8 ).
Identification of Essential Amino Acid Residues in the TILL Motif.
Some of the conserved residues within the TILL motif correspond to residues in the BB-loop that form a key salt bridge; namely, Glu-533 or Glu-534 with Arg-549. In addition, the TILL contains a conserved valine at position 553 that corresponds to an essential residue in Drosophila Toll and murine TLR4 (44, 46) . To test the hypothesis that the TILL domain forms a structure similar to a BB-loop, we mutated the charged residues to Ala or Val-553 to His and evaluated the ability to activate IL-17-dependent signaling. IL-17RA KO cells were transiently transfected with IL-17RA.FL or the mutant receptors and a 24p3 promoter-luciferase reporter (38) . Surprisingly, all of the putative salt bridge mutants were fully competent to activate the reporter in response to IL-17 and/or TNF␣ (Fig. 4A) . However, the IL-17RA.V553H mutant showed considerably impaired signaling activity. Therefore, stable IL-17RA KO cells expressing IL-17RA.V553H were created to determine whether this mutant was defective in other TILL-dependent signaling events. In three independent lines, IL-17-mediated IL-6 expression was blocked (Fig. 4B) . Similarly, IL-17-mediated induction of 24p3, CXCL5, C/EBP␦, C/EBP␤, and NF-B were impaired (Figs. 2D and 4 C-E) . Thus, the TILL domain appears to contain some structural similarities to a genuine TIR domain but also has important disparities that are likely to be the basis for differences between IL-17RA and classic TIR domain-containing receptors.
IL-17RA Does Not Use Canonical TIR Signaling
Intermediates. In the IL-1/TLR family, the TIR domain is critical for engaging adaptors that lead to activation of TRAF6. There is convincing evidence that TRAF6 is a key downstream mediator of IL-17-dependent signal transduction, and IL-17RA can bind TRAF6 in overexpression systems (40) . However, IL-17RA does not contain a canonical TRAF6-binding motif (51) and, thus, is unlikely to bind TRAF6 directly. Because TILL resembles the TIR BB-loop, we speculated that IL-17 might employ the canonical TLR and IL-1R adaptor, MyD88. However, MyD88-deficient fibroblasts induced potent IL-17-dependent IL-6 expression (Fig. 5) . Similarly, TRIF-deficient cells also induced strong IL-17-dependent signaling (Fig. 5) . Coupled with the recent finding that IL-17 activates Act1 (41, 42) , these data suggest that immediate proximal mediators of IL-17R signaling are distinct from IL-1/TLR family adaptors.
Discussion
Cytokines receptors are classified into limited groups based on sequence homology, which generally share common signaling pathways. For example, Type I and II hematopoietin receptors use the JAK-STAT pathway, whereas TIR-domain receptors typically activate TRAF6 and NF-B. Because the IL-17R superfamily shares only minimal homology with other receptors, we undertook to delineate regions within IL-17RA critical for signal transduction. We found that the ''SEFIR'' domain, predicted to be a potential signaling motif with distant similarity to TIR domains (39) , is indeed required for IL-17-induced signaling. Consistent with this, Qian et al. (42) recently showed that a SEFIR deletion in human IL-17RA fails to bind Act1, a newly identified IL-17RA signaling molecule. In addition, we identified a region downstream of the SEFIR domain termed a TILL that is critically important for activation of NF-B and C/EBP transcription factors and subsequent gene expression. Detailed mutagenesis of TILL indicates that this region contains features similar to TIR domains such as a key residue at position V553, analogous to Toll and TLR4, but also important differences, such as the lack of an apparent salt bridge (44) . Furthermore, the C-terminal location of the TILL with respect to the SEFIR is different from TIR BB-loops, which link the second ␤-strand to the second ␣-helix (45). Therefore, it will be interesting to determine whether the TILL adopts a conformation similar to a BB-loop, or links to an as-yet-unidentified functional domain in IL-17RA. Surprisingly, we also discovered a distal domain in the IL-17RA tail that contributes to activation of C/EBP␤ and is necessary for optimal induction of a subset of IL-17 target genes. To date, we have found no homology of this subdomain to other molecules.
Molecular studies of IL-17RA have been hindered by its widespread expression. In the present study, we developed an unambiguous system to analyze IL-17RA by reconstituting IL-17RA mutants in fibroblasts from IL-17RA KO mice (30) . Fibroblasts and other mesenchymal cells contribute to IL-17-mediated pathology in rheumatoid synovium, probably by expression of inflammatory effectors with joint-destructive potential (20, 29) . Importantly, IL-17RA KO cells reconstituted with IL-17RA activate the same genes that are induced by IL-17 in cultured fibroblasts (38, 47) . Although the in vivo relevance of many IL-17 target genes has not been determined, IL-17-mediated regulation of neutrophil migration via CXC chemokines is well established in infection models (30, 52) . For example, we found that IL-17RA KO mice are highly susceptible to periodontal infections; this phenotype is due largely to a severe reduction in expression of CXCL1 and CXCL5, leading to a failure of neutrophils to reach the infected gingiva (33) .
Although IL-17RA was initially considered to be structurally unique (34), a bioinformatics study predicted a ''SEFIR'' region with homology to TIR domains (39) . However, important elements were absent in this alignment, such as the BB-loop. We found a region with homology to a BB-loop within IL-17RA located downstream and slightly overlapping the SEFIR domain (Fig. 1) , which we termed a TILL. Deletion of either SEFIR or TILL eliminated NF-B-and C/EBP-dependent signaling as well as ERK activation (Figs. 2-4) . Thus, the SEFIR and TILL domains comprise an extended functional region in IL-17RA required for activating downstream events. Although the three-dimensional structure of this motif remains unknown, we identified an essential amino residue, V553. This residue lies in an analogous position to Pro-712 in TLR4, which is altered to histidine in LPS-resistant C3H/HeJ mice (46) . In TLRs, this residue is not required for structural integrity (44) , but whether this is also true for IL-17 receptors remains to be determined. Unlike true TIR domains, there is no evidence for a stabilizing salt bridge in the TILL, because the E533A, E534A, and R549A mutants all reconstituted IL-17 signaling indistinguishably from wild type (Fig. 4A) . Accordingly, it was not surprising that IL-17 signals independently of MyD88 and TRIF, adaptors that interact with TIR domains (Fig. 5) . It was discovered recently that Act1 may be a key link to IL-17R signaling, and Act1 could be coimmunoprecipitated with IL-17RA through the Act1 SEFIR-like domain (41) . Thus, homotypic SEFIR interactions may be analogous to TIR-TIR associations.
Whereas NF-B is an important IL-17 signaling pathway, C/EBP transcription factors are also vital for induction of many IL-17 target genes (43) . Our microarray studies showed that C/EBP␦ and C/EBP␤ themselves are induced by IL-17, suggesting a positive feedback loop whereby up-regulation of C/EBP amplifies expression of IL-6 and other target genes (38, 43) . Although induced only mildly at the mRNA level, protein expression of both C/EBP␤ and C/EBP␦ is strongly enhanced by IL-17 (Fig. 3) . Reconstitution of C/EBP␤␦ KO cells with C/EBP␤ or C/EBP␦ can rescue IL-17-dependent IL-6 secretion and 24p3 promoter activity (53), suggesting that there is considerable redundancy in C/EBP function. However, the present study shows that regulation of C/EBP␦ and C/EBP␤ by IL-17 occurs by separable pathways, because the IL-17RA⌬665 mutant induces normal expression of C/EBP␦ but not C/EBP␤ (Fig. 3) . Moreover, IL-17RA⌬665 activates some IL-17-dependent genes normally (IL-6, CXCL5, and 24p3), but not others (CCL2 and CCL7). Therefore, IL-17 uses C/EBP␦ and C/EBP␤ differentially to control gene expression, and these factors are clearly not entirely redundant.
Regulation of C/EBP proteins is highly complex. C/EBP␦ is controlled primarily by expression rather than by posttranslational modifications. At the transcriptional level, both 5Ј and 3Ј promoter/ enhancer regions have been described (54, 55) , although the mechanism by which IL-17 regulates C/EBP␦ is undefined. Our data indicate that C/EBP␦ expression is downstream of SEFIR/ TILL, perhaps mediated by NF-B or ERK (Fig. 3) . In contrast, C/EBP␤ is largely controlled posttranslationally. C/EBP␤ exists in multiple isoforms (56) , and IL-17 seems to preferentially induce the largest of these, LAP* (Fig. 3) . Moreover, C/EBP␤ is phosphorylated on several sites, and numerous serine-threonine kinases have (61, 62) were treated with IL-17 and/or TNF␣, poly I:C (12.5 g/ml), or LPS (10 ng/ml) for 6 or 24 h, and IL-6 was assessed in triplicate.
been implicated in its regulation (55) (56) (57) (58) . Determining the target sites on C/EBP␤ required for IL-17-mediated activation and the upstream signals responsible will be essential for fully understanding the IL-17 signaling cascade.
Mapping functional domains in cytokine receptors has been enlightening in terms of understanding signal transduction. In the IL-2R, different tyrosine residues preferentially mediate STAT5 versus phosphatidylinositol 3-kinase (59) . Similarly, separable regions within gp130 are required for STAT activation versus MAPK activation and mediate different activities in vivo (60) . The present report reveals two separable motifs involved in IL-17RA signal transduction (SI Fig. 8) . The biological significance of these signaling pathways is still not fully known, but this work sets the stage for probing IL-17R superfamily members functions in vivo.
Materials and Methods
Cell Culture and Luciferase Assays. IL-17RA
KO fibroblasts from IL-17RA KO mice (30, 36) were immortalized with the SV40 T antigen. Murine embryonic fibroblasts were obtained from TRIF Ϫ/Ϫ (61) and MyD88 Ϫ/Ϫ mice (62) . All cells were cultured in ␣-MEM (Sigma, St. Louis, MO), with 10% FBS and antibiotics (Invitrogen, Carlsbad, CA). Cells were transfected with FuGENE 6 (Roche, Indianapolis, IN) and stable lines were selected in Zeocin (Invitrogen). Cytokines were from R&D Systems (Minneapolis, MN). LPS and Poly I:C were from Sigma. Luciferase assays were performed as described (38) .
Plasmids. IL-17RA was generated by RT-PCR from HT-2 cells. Mutations were made by PCR and subcloned in pcDNA3.1-Zeocin (Invitrogen). Point mutations were made with the QuikChange mutagenesis kit (Stratagene, La Jolla, CA) and confirmed by sequencing.
ELISA and Flow Cytometry. IL-6 ELISAs were performed with commercial kits (eBioscience, San Diego, CA). For FACS, 10 6 cells were stained with mAbs M177, M750, or M751, followed by anti-rat-PE (BD PharMingen, San Jose, CA). For binding studies, a cDNA encoding huIL17 fused to huFc (IgG1) was expressed in COS cells and purified over Protein A columns. Cells were stained with huIL17.Fc, followed by anti-huIgG-APC (Jackson Immunoresearch, West Grove, PA). Data were analyzed on a FACSCalibur with Cell Quest software (BD Biosciences, San Jose, CA).
Western Blotting, Immunoprecipitation, and EMSA. EMSAs were performed as described (35) . Antibodies to C/EBP and histone were from Santa Cruz Biotechnology (Santa Cruz, CA), HA Abs were from Roche, and ERK Abs were from Cell Signaling Technology (Beverly, MA).
